Johns Hopkins ABX Guide
Amikacin
Amikacin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Amikacin sulfate indicated in the short-term treatment of serious infections due to susceptible organisms
- [With the exception of uncomplicated UTI, aminoglycosides are generally used in combination for serious infections including treatment of Pseudomonas aeruginosa.]
- Bacterial septicemia (including neonatal sepsis)
- Respiratory tract infections
- Bone and joint infections
- Central nervous system infections
- Skin and soft tissue infections (including burns, postoperative infections)
- Intra-abdominal infections
- Complicated and recurrent urinary tract infections.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
- Tuberculosis
- Non-tubercular mycobacterial (NTM) infections, MAI
- Nocardia
- Aerosolized amikacin has been used for the management of cystic fibrosis exacerbations
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Amikacin sulfate indicated in the short-term treatment of serious infections due to susceptible organisms
- [With the exception of uncomplicated UTI, aminoglycosides are generally used in combination for serious infections including treatment of Pseudomonas aeruginosa.]
- Bacterial septicemia (including neonatal sepsis)
- Respiratory tract infections
- Bone and joint infections
- Central nervous system infections
- Skin and soft tissue infections (including burns, postoperative infections)
- Intra-abdominal infections
- Complicated and recurrent urinary tract infections.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
- Tuberculosis
- Non-tubercular mycobacterial (NTM) infections, MAI
- Nocardia
- Aerosolized amikacin has been used for the management of cystic fibrosis exacerbations
There's more to see -- the rest of this entry is available only to subscribers.
Last updated: March 8, 2020
Citation
Dzintars, Kathryn. "Amikacin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540015/all/Amikacin.
Dzintars K. Amikacin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540015/all/Amikacin. Accessed April 12, 2021.
Dzintars, K. (2020). Amikacin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540015/all/Amikacin
Dzintars K. Amikacin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2021 April 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540015/all/Amikacin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Amikacin
ID - 540015
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2020/03/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540015/all/Amikacin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
